OncoMatch/Clinical Trials/NCT06698484
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)
Is NCT06698484 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies CAR-T cells for relapsed/refractory b- cell non-hodgkin lymphoma.
Treatment: CAR-T cells — A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: second-line treatment — refractory
refractory to second-line treatment
Must have received: first-line treatment — relapsed
relapsed after first-line treatment with no available curative options such as autologous or allogeneic haematopoietic stem cell transplantation (HSCT)
Cannot have received: autologous or allogeneic stem cell transplant
Exception: allowed if >12 weeks before enrolment
Receiving autologous or allogeneic stem cell transplant within 12 weeks of enrolment
Lab requirements
Blood counts
absolute neutrophil count ≥ 1500/μl, haemoglobin level ≥ 7 g/dl, platelets ≥ 50000/μl
Kidney function
creatinine clearance >40 ml/min
Liver function
serum alanine transaminase (alt) < 5 times the normal value, serum bilirubin < 3 times the normal value
Cardiac function
left ventricular ejection fraction > 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify